Axatilimab (Niktimvo)
Mechanism of action
colony stimulating factor-1 receptor-blocking antibody
Diseases for which it is established
History of changes in FDA indication
- 2024-08-14: Initial approval for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. (Based on AGAVE-201)
Also known as
- Generic name: axatilimab-csfr
- Brand name: Niktimvo